MiR-26b suppresses tumor cell proliferation, migration and invasion by directly targeting COX-2 in lung cancer

European Review for Medical and Pharmacological Sciences

Volumn 19, Issue 24, 2015, Pages 4728-4737

  Xia, M ^a   Duan, M L ^a   Tong, J H ^a   Xu, J G ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

COX 2; MiR 26b; NSCLC

Indexed keywords

CYCLOOXYGENASE 2; LENTIVIRUS VECTOR; MICRORNA; MICRORNA 62B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; MIRN26A MICRORNA, HUMAN; TUMOR MARKER;

3' UNTRANSLATED REGION; A549 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BIOINFORMATICS; CELL COUNTING; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUCIFERASE ASSAY; LUNG CANCER; MOUSE; MTT ASSAY; NONHUMAN; TUMOR CELL; UPREGULATION; WESTERN BLOTTING; CELL MOTION; GENE EXPRESSION; GENETICS; LUNG TUMOR; NON SMALL CELL LUNG CANCER; PROGNOSIS; TUMOR CELL LINE; TUMOR INVASION;

BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYCLOOXYGENASE 2; FEMALE; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; MICRORNAS; NEOPLASM INVASIVENESS; PROGNOSIS;

EID: 84958839158     PISSN: 11283602     EISSN: 22840729     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. RIDGE CA, MCERLEAN AM, GINSBERG MS. Epidemiology of lung cancer. Semin Intervent Radiol 2013; 30: 93-98.
2. SIEGEL R, NAISHADHAM D, JEMAL A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
3. ZHAN P, QIAN Q, YU LK. Prognostic value of COX-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis. J Thorac Dis 2013; 5: 40-47.
4. KARAVITIS J, ZHANG M. COX2 regulation of breast cancer bone metastasis. Oncoimmunology 2013; 2: 641.
5. EDGE SB, SOBIN LH, PAGE DL, GOSPODAROWICZ MK, GREENE FL, WINCHESTER DP. Re: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2005; 97: 463-464.
6. TSUJII M, DUBOIS RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493-501.
7. HOWE LR. Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res 2007; 9: 210.
8. TYAGI A1, AGARWAL C, DWYER-NIELD LD, SINGH RP, MALKINSON AM, AGARWAL R. Silibinin modulates TNF-alpha and IFN-gamma mediated signaling to regulate COX2 and iNOS expression in tumorigenic mouse lung epithelial LM2 cells. Mol Carcinog 2012; 51: 832-842.
9. MARTÍN SANZ P, HORTELANO S, BOSCA L, CASADO M. Cyclooxygenase 2: understanding the pathophysiological role through genetically altered mouse models. Front Biosci 2006; 11: 2876-2888.
10. MASFERRER JL, LEAHY KM, KOKI AT, ZWEIFEL BS, SETTLE SL, WOERNER BM, EDWARDS DA, FLICKINGER AG, MOORE RJ, SEIBERT K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60: 1306-1311.
11. KRZYSTYNIAK KL. Current strategies for anticancer chemoprevention and chemoprotcction. Acta Pol Pharm 2002; 59: 473-478.
12. BARTEL DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
13. HE L, HANNON GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004; 5: 522-531.
14. FARH KK, GRIMSON A, JAN C, LEWIS BP, JOHNSTON WK, LIM LP, BURGE CB, BARTEL DP. The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science 2005; 310: 1817-1821.
15. WU D, ZHOU Y, PAN H, ZHOU J, FAN Y, QU P. microRNA-99a inhibiting cell proliferation, migration and invasion by targeting fibroblast growth factor receptor 3 in bladder cancer. Oncol Lett 2014; 7: 1219-1224.
16. SLABY O, SVOBODA M, FABIAN P, SMERDOVA T, KNOFLICKOVA D, BEDNARIKOVA M, NENUTIL R, VYZULA R. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 2008; 72: 397-402.
17. SHIVDASANI RA. MicroRNAs: regulators of gene expression and cell differentiation. Blood 2006; 108: 3646-3653.
18. SHAN X, MIAO Y, FAN R, QIAN H, CHEN P, LIU H, YAN X, LI J, ZHOU F. MiR-590-5P inhibits growth of HepG2 cells via decrease of S100A10 expression and inhibition of the Wnt pathway. Int J Mol Sci 2013; 14: 8556-8569.
19. CHAKRABARTY A, TRANGUCH S, DAIKOKU T, JENSEN K, FURNEAUX H, DEY SK. MicroRNA regulation of cyclooxygenase-2 during embryo implantation. Proc Natl Acad Sci U S A 2007; 104: 15144-15149.
20. GAO J, LI L, WU M, LIU M, XIE X, GUO J, TANG H, XIE X. MiR-26a inhibits proliferation and migration of breast cancer through repression of MCL-1. PLoS One 2013; 8: e65138.
21. LIN Y, CHEN H, HU Z, MAO Y, XU X, ZHU Y, XU X, WU J, LI S, MAO Q, ZHENG X, XIE L. miR-26a inhibits proliferation and motility in bladder cancer by targeting HMGA1. FEBS Lett 2013; 587: 2467-2473.
22. DENG M, TANG HL, LU XH, LIU MY, LU XM, GU YX, LIU JF, HE ZM. miR-26a suppresses tumor growth and metastasis by targeting FGF9 in gastric cancer. PLoS One 2013; 8: e72662.
23. ZHAO S, YE X, XIAO L, LIAN X, FENG Y, LI F, LI L. MiR-26a inhibits prostate cancer progression by repression of Wnt5a. Tumor Biol 2014; 35: 9725-9733.
24. VERGHESE ET, DRURY R, GREEN CA, HOLLIDAY DL, LU X, NASH C, SPEIRS V, THORNE JL, THYGESEN HH, ZOUGMAN A, HULL MA, HANBY AM, HUGHES TA. MiR-26b is down-regulated in carcinoma-associated fibroblasts from ER-positive breast cancers leading to enhanced cell migration and invasion. J Pathol 2013; 231: 388-399.
25. LIANG X, LIU Y, ZENG L, YU C, HU Z, ZHOU Q, YANG Z. miR-101 inhibits the G1-to-S phase transition of cervical cancer cells by targeting Fos. Int J Gynecol Cancer 2014; 24: 1165-1172.
26. SHENG Y, LI J, ZOU C, WANG S, CAO Y, ZHANG J, HUANG A, TANG H. Downregulation of miR-101-3p by hepatitis B virus promotes proliferation and migration of hepatocellular carcinoma cells by targeting Rab5a. Arch Virol 2014; 159: 2397-2410.
27. KWON Y, KIM Y, EOM S, KIM M, PARK D, KIM H, NOH K, LEE H, LEE YS, CHOE J, KIM YM, JEOUNG D. MicroRNA-26a/-26b-COX-2-MIP-2 Loop Regulates Allergic Inflammation and Allergic Inflammationpromoted Enhanced Tumorigenic and Metastatic Potential of Cancer Cells. J Biol Chem 2015; 290: 14245-14266.
28. BANDRÉS E, CUBEDO E, AGIRRE X, MALUMBRES R, ZÁRATE R, RAMIREZ N, ABAJO A, NAVARRO A, MORENO I, MONZÓ M, GARCÍA-FONCILLAS J. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer 2006; 5: 29.
29. LI W, LI H, LI J, WANG H, ZHAO H, ZHANG L, XIA Y, YE Z, GAO J, DAI J, WANG H, GUO Y. Self-assembled supramolecular nano vesicles for safe and highly efficient gene delivery to solid tumors. Int J nanomedicine 2012; 7: 4661-4677.
30. WU C, LI H, ZHAO H, ZHANG W, CHEN Y, YUE Z, LU Q, WAN Y, TIAN X, DENG A. Potentiating antilymphoma efficacy of chemotherapy using a liposome for integration of CD20 targeting, ultra-violet irradiation polymerizing, and controlled drug delivery. Nanoscale Res Lett 2014; 9: 447.
31. JOSHI P, MIDDLETON J, JEON YJ, GAROFALO M. MicroRNAs in lung cancer. World J Methodol 2014; 4: 59-72.
32. SMITH WL, LANGENBACH R. Why there are two cyclooxygenase isozymes. J Clin Invest 2001; 107: 1491-1495.
33. MASCAUX C, MARTIN B, PAESMANS M, BERGHMANS T, DUSART M, HALLER A, LOTHAIRE P, MEERT AP, LAFITTE JJ, SCULIER JP. Has Cox-2 a prognostic role in nonsmall-cell lung cancer? A systematic review of the literature with meta-analysis of the survival results. Br J Cancer 2006; 95: 139-145.